Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02421575 · ClinicalTrials.gov registry record · Early Phase 1
Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
A Early Phase 1 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
NCT02421575 is a Early Phase 1 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 4 participants.
The verdict
NCT02421575, a Early Phase 1 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
This phase 0 trial studies hydroxychloroquine in blocking autophagy in patients with prostate cancer who are undergoing surgery or active surveillance. Autophagy is a process in which cells break down some parts of themselves to stay alive during times of stress, such as starvation. This may allow cancer cells to survive damage from chemotherapy. Hydroxychloroquine may block this process from happening.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Hydroxychloroquine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2012-07 |
| Est. Completion | 2016-02-26 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02421575
The ClinicalTrials.gov registry entry for NCT02421575 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02421575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02421575 about?
NCT02421575 is a clinical study titled "Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance". This phase 0 trial studies hydroxychloroquine in blocking autophagy in patients with prostate cancer who are undergoing surgery or active surveillance. Autophagy is a process in which cells break down some parts of themselves to stay alive during times of stress, such as starvation. This may allow c...
What is the current status of trial NCT02421575?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2012-07. Estimated completion is 2016-02-26.
What interventions are being tested in trial NCT02421575?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Hydroxychloroquine (DRUG).
Who is sponsoring clinical trial NCT02421575?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.